| Literature DB >> 32592261 |
Keiichi Yamaguchi1, Nobukazu Kasai1,2, Nanako Hayashi1, Haruka Yatsutani1, Olivier Girard3, Kazushige Goto1.
Abstract
We investigated performance, energy metabolism, acid-base balance, and endocrine responses to repeated-sprint exercise in hot and/or hypoxic environment. In a single-blind, cross-over study, 10 male highly trained athletes completed a repeated cycle sprint exercise (3 sets of 3 × 10-s maximal sprints with 40-s passive recovery) under four conditions (control [CON; 20℃, 50% rH, FiO2 : 20.9%; sea level], hypoxia [HYP; 20℃, 50% rH, FiO2 : 14.5%; a simulated altitude of 3,000 m], hot [HOT; 35℃, 50% rH, FiO2 : 20.9%; sea level], and hot + hypoxia [HH; 35℃, 50% rH, FiO2 : 14.5%; a simulated altitude of 3,000 m]). Changes in power output, muscle and skin temperatures, and respiratory oxygen uptake were measured. Peak (CON: 912 ± 26 W, 95% confidence interval [CI]: 862-962 W, HYP: 915 ± 28 W [CI: 860-970 W], HOT: 937 ± 26 W [CI: 887-987 W], HH: 937 ± 26 W [CI: 886-987 W]) and mean (CON: 808 ± 22 W [CI: 765-851 W], HYP: 810 ± 23 W [CI: 765-855 W], HOT: 825 ± 22 W [CI: 781-868 W], HH: 824 ± 25 W [CI: 776-873 W]) power outputs were significantly greater when exercising in heat conditions (HOT and HH) during the first sprint (p < .05). Heat exposure (HOT and HH) elevated muscle and skin temperatures compared to other conditions (p < .05). Oxygen uptake and arterial oxygen saturation were significantly lower in hypoxic conditions (HYP and HH) versus the other conditions (p < .05). In summary, additional heat stress when sprinting repeatedly in hypoxia improved performance (early during exercise), while maintaining low arterial oxygen saturation.Entities:
Keywords: combination of stressors; heat stress; hypoxia; repeated-sprints
Mesh:
Year: 2020 PMID: 32592261 PMCID: PMC7319945 DOI: 10.14814/phy2.14466
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
FIGURE 1Protocol overview
FIGURE 2Changes in peak (a) and mean power outputs (b) during exercise. Values are means ± SE. *: p < .05 vs. sprint 1, b: p < .05 CON vs. HOT, c: p < .05 CON vs. HH, d: p < .05 HYP vs. HOT, e: p < .05 HYP vs. HH
FIGURE 3Changes in muscle (a) and skin temperatures (b) during exercise. Values are means ± SE. *: p < .05 vs. sprint 1, b: p < .05 CON vs. HOT, c: p < .05 CON vs. HH, d: p < .05 HYP vs. HOT, e: p < .05 HYP vs. HH
Cardiorespiratory variables during each set of exercise
| Set 1 | Set 2 | Set 3 | Average | ANOVA | |||
|---|---|---|---|---|---|---|---|
| Interaction | Condition | Time | |||||
| VO2 (mL·min−1) | 0.507 | <0.001 | 0.134 | ||||
| CON | 2,266 ± 66 (2137–2395) | 2,301 ± 60 (2183–2418) | 2,260 ± 55 (2152–2368) | 2,275 ± 59 (2160–2391) | |||
| HYP | 1901 ± 61 | 1891 ± 58 | 1,850 ± 64 | 1881 ± 59 | |||
| HOT | 2,422 ± 70 | 2,458 ± 50 | 2,417 ± 62 | 2,432 ± 57 | |||
| HH | 2029 ± 76 | 2050 ± 75 | 1959 ± 74 | 2013 ± 72 | |||
| VCO2 (mL·min−1) | 0.111 | 0.001 | <0.001 | ||||
| CON | 2,666 ± 78 (2512–2819) | 2,302 ± 68 | 2,117 ± 60 | 2,361 ± 59 (2246–2477) | |||
| HYP | 2,749 ± 78 (2597–2902) | 2,256 ± 68 | 2028 ± 84 | 2,344 ± 67 (2212–2477) | |||
| HOT | 2,878 ± 86 | 2,497 ± 74 | 2,262 ± 76*‡ (2112–2412) | 2,546 ± 65 | |||
| HH | 2,849 ± 106 (2642–3056) | 2,482 ± 74 | 2,152 ± 75 | 2,494 ± 71 | |||
| VE (L·min−1) | 0.070 | <0.001 | 0.064 | ||||
| CON | 95.9 ± 4.5 (87.0–104.8) | 104.8 ± 5.4 (94.2–115.4) | 105.9 ± 6.5 (93.2–118.6) | 102.2 ± 5.2 (92.1–112.3) | |||
| HYP | 106.0 ± 5.7 | 112.6 ± 5.9 | 109.7 ± 8.2 (93.6–125.9) | 109.4 ± 6.2 | |||
| HOT | 98.3 ± 3.9 (90.7–105.8) | 107.5 ± 4.6 (98.5–116.5) | 107.0 ± 6.4 (94.5–119.6) | 104.3 ± 4.4 (95.7–112.8) | |||
| HH | 105.1 ± 5.7 | 119.4 ± 6.7 | 112.4 ± 6.8 (99.1–125.6) | 112.3 ± 6.0 | |||
| HR (bpm) | 0.439 | 0.056 | 0.106 | ||||
| CON | 147 ± 3 (141–153) | 153 ± 3 (147–159) | 154 ± 3 (147–161) | 151 ± 3 (145–157) | |||
| HYP | 142 ± 10 (122–161) | 153 ± 4 (145–160) | 151 ± 4 (142–159) | 148 ± 5 (139–158) | |||
| HOT | 154 ± 3 (147–160) | 158 ± 2 (154–163) | 152 ± 3 (146–159) | 155 ± 2 (151–158) | |||
| HH | 156 ± 3 (149–163) | 160 ± 4 (152–168) | 157 ± 5 (147–167) | 158 ± 4 (150–166) | |||
| SpO2 (%) | 0.321 | < 0.001 | 0.361 | ||||
| CON | 92.6 ± 1.2 (90.2–94.9) | 90.6 ± 2.2 (86.3–94.8) | 92.2 ± 4.3 (89.6–94.9) | 91.8 ± 1.4 (89.1–94.4) | |||
| HYP | 85.0 ± 1.4 | 86.1 ± 0.7 | 86.3 ± 2.1 | 85.8 ± 0.8 | |||
| HOT | 93.3 ± 1.0 | 92.6 ± 1.3 | 94.0 ± 1.5 | 93.3 ± 0.8 | |||
| HH | 86.9 ± 0.7 | 85.6 ± 0.7 | 85.8 ± 2.0 | 86.1 ± 0.6 | |||
Values are means ± SE (95% CI).
p < .05 vs. set 1,
p < .05 vs. CON,
p < .05 vs. HYP,
p < .05 vs. HOT.
FIGURE 4Plasma adrenaline (a), noradrenaline (b), and glucagon concentrations (c) before and after exercise. Values are means ± SE. *: p < .05 vs. Pre, †: p < .05 vs. CON
Blood lactate, glucose concentrations and blood gas variables before and after exercise
| Baseline | Set 1 | Set 2 | Set 3 | Post‐exercise | ANOVA | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 min | 5 min | 30 min | 60 min | Interaction | Condition | Time | |||||
| Lactate (mmol·L−1) | 0.858 | 0.643 | <0.001 | ||||||||
| CON | 1.1 ± 0.1 (0.9–1.3) | 10.2 ± 1.0 | 15.5 ± 1.5 | 17.1 ± 1.2 | 16.1 ± 1.0 | 16.3 ± 1.0 | 9.9 ± 0.9 | 4.9 ± 0.5 | |||
| HYP | 1.3 ± 0.1 (1.1–1.5) | 11.0 ± 1.1 | 15.6 ± 0.8 | 17.3 ± 1.1 | 15.7 ± 0.9 | 16.1 ± 0.9 | 10.4 ± 0.7 | 5.2 ± 0.7 | |||
| HOT | 1.3 ± 0.1 (1.1–1.5) | 10.9 ± 0.6 | 14.2 ± 1.0 | 16.5 ± 1.0 | 15.9 ± 0.9 | 16.3 ± 0.8 | 9.2 ± 0.9 | 4.3 ± 0.4 | |||
| HH | 1.2 ± 0.1 (1.0–1.4) | 11.3 ± 0.6 | 15.3 ± 0.6 | 17.2 ± 1.1 | 16.5 ± 0.8 | 15.8 ± 0.7 | 10.4 ± 0.7 | 4.7 ± 0.5 | |||
| Glucose (mg·dL−1) | 0.092 | 0.247 | <0.001 | ||||||||
| CON | 83 ± 2 (78–87) | 93 ± 3 | 96 ± 4 | 93 ± 3 | 101 ± 4 | 101 ± 5 | 89 ± 4 (81–97) | 75 ± 3 (69–81) | |||
| HYP | 88 ± 2 (84–92) | 88 ± 3 (82–93) | 94 ± 3 (88–101) | 97 ± 6 (86–108) | 100 ± 7 | 104 ± 7 (90–117) | 93 ± 6 (82–105) | 80 ± 3 (75–85) | |||
| HOT | 86 ± 2 (82–90) | 97 ± 2 | 98 ± 3 | 95 ± 3 (88–102) | 100 ± 4 | 101 ± 4 | 91 ± 5 (81–101) | 84 ± 3 (77–90) | |||
| HH | 86 ± 3 (81–92) | 95 ± 2 (90–99) | 97 ± 3 (91–103) | 98 ± 4 (91–106) | 109 ± 6 | 108 ± 5 | 99 ± 7 | 87 ± 5 (78–96) | |||
| PO2 (kPa) | 0.164 | 0.200 | <0.001 | ||||||||
| CON | 8.85 ± 0.64 (7.60–10.10) | 5.18 ± 0.84 | 11.75 ± 0.40 | 13.11 ± 0.48 | 10.49 ± 0.52 (9.47–11.51) | 8.35 ± 0.62 (7.13–9.57) | |||||
| HYP | 8.51 ± 0.64 (7.26–9.76) | 3.98 ± 0.51 | 10.94 ± 0.59 | 12.02 ± 0.50 | 9.09 ± 0.69 (7.74–10.44) | 7.47 ± 0.77 (5.96–8.98) | |||||
| HOT | 8.30 ± 0.56 (7.20–9.40) | 6.41 ± 0.73 (4.98–7.84) | 10.17 ± 0.46 (9.27–11.07) | 12.06 ± 0.56 | 10.22 ± 0.67 | 8.16 ± 0.81 (6.57–9.75) | |||||
| HH | 8.74 ± 1.02 (6.74–10.74) | 6.05 ± 0.67 | 11.52 ± 0.42 | 11.81 ± 0.39 | 10.39 ± 0.36 (9.68–11.10) | 8.37 ± 0.67 (7.06–9.68) | |||||
| PCO2 (kPa) | <0.001 | 0.044 | <0.001 | ||||||||
| CON | 5.64 ± 0.14 (5.37–5.91) | 6.09 ± 0.49 (5.13–7.05) | 4.07 ± 0.23 | 3.84 ± 0.16 | 4.28 ± 0.11 | 5.14 ± 0.17 (4.81–5.47) | |||||
| HYP | 5.70 ± 0.11 (5.48–5.92) | 6.02 ± 0.33 (5.37–6.67) | 4.08 ± 0.18 | 4.02 ± 0.10 | 4.37 ± 0.16 | 5.20 ± 0.17 (4.87–5.53) | |||||
| HOT | 5.71 ± 0.19 (5.34–6.08) | 5.19 ± 0.36 (4.48–5.90) | 4.15 ± 0.23 | 3.91 ± 0.18 | 4.29 ± 0.08 | 5.20 ± 0.12 (4.96–5.44) | |||||
| HH | 5.98 ± 0.21 (5.57–6.39) | 4.51 ± 0.29 | 3.82 ± 0.10 | 3.84 ± 0.12 | 4.13 ± 0.11 | 5.12 ± 0.15 | |||||
Values are means ± SE (95% CI).
p < .05 vs. Baseline,
p < .05 vs. CON,
p < .05 vs. HYP.
Acid‐base balance and plasma volume shift before and after exercise
| Baseline | Set 3 | Post‐exercise | ANOVA | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 3 min | 5 min | 30 min | 60 min | Interaction | Condition | Time | |||
| pH | 0.818 | 0.016 | <0.001 | ||||||
| CON | 7.42 ± 0.005 (7.41–7.42) | 7.22 ± 0.036 | 7.19 ± 0.014 | 7.19 ± 0.013 | 7.33 ± 0.016 | 7.38 ± 0.011 (7.36–7.40) | |||
| HYP | 7.41 ± 0.005 (7.40–7.42) | 7.20 ± 0.016 | 7.19 ± 0.015 | 7.19 ± 0.017 | 7.33 ± 0.012 | 7.39 ± 0.009 (7.37–7.41) | |||
| HOT | 7.41 ± 0.004 (7.40–7.41) | 7.21 ± 0.015 | 7.21 ± 0.009 | 7.21 ± 0.010 | 7.35 ± 0.012 | 7.39 ± 0.006 (7.38–7.40) | |||
| HH | 7.41 ± 0.010 (7.39–7.43) | 7.24 ± 0.012 | 7.22 ± 0.014 | 7.22 ± 0.013 | 7.36 ± 0.010 | 7.40 ± 0.010 (7.38–7.42) | |||
| BE (mmol·L−1) | 0.014 | 0.495 | <0.001 | ||||||
| CON | 1.7 ± 0.5 (0.7 ~ 2.7) | −9.4 ± 0.7 | −12.5 ± 0.4 | −13.1 ± 0.5 | −7.5 ± 0.7 | −2.2 ± 0.6 | |||
| HYP | 1.5 ± 0.4 (0.7 ~ 2.3) | −8.6 ± 0.8 | −12.5 ± 0.6 | −12.7 ± 0.6 | −7.1 ± 0.7 | −1.5 ± 0.5 | |||
| HOT | 1.3 ± 0.6 (0.1 ~ 2.5) | −9.2 ± 0.4 | −11.5 ± 0.4 | −12.3 ± 0.4 | −6.8 ± 0.5 | −1.8 ± 0.3 | |||
| HH | 3.0 ± 0.3 (2.4 ~ 3.6) | −9.2 ± 0.9 | −12.2 ± 0.7 | −12.4 ± 0.7 | −6.5 ± 0.7 | −1.0 ± 0.6 | |||
| HCO3 ‐ (mmol·L−1) | <0.001 | 0.561 | <0.001 | ||||||
| CON | 26.5 ± 0.6 (25.3–27.7) | 13.0 ± 0.9 | 9.1 ± 0.4 | 8.8 ± 0.4 | 15.0 ± 0.7 | 21.2 ± 0.8 | |||
| HYP | 26.5 ± 0.5 (25.5–27.5) | 14.0 ± 1.1 | 9.6 ± 0.8 | 9.5 ± 0.7 | 15.7 ± 0.9 | 21.4 ± 0.9 | |||
| HOT | 26.3 ± 0.8 (24.7–27.9) | 12.0 ± 0.7 | 9.9 ± 0.7 | 9.6 ± 0.5 | 16.2 ± 0.6 | 22.5 ± 0.7 | |||
| HH | 28.0 ± 0.5 (27.0–29.0) | 11.5 ± 1.2 | 9.7 ± 0.5 | 9.8 ± 0.5 | 15.8 ± 0.7 | 22.7 ± 0.7 | |||
| ΔPV (%) | 0.031 | 0.606 | <0.001 | ||||||
| CON | 0.0 ± 0.0 (0.0–0.0) | −20.8 ± 1.4 | −19.6 ± 1.2 | −18.1 ± 1.7 | −8.9 ± 1.8 | −5.2 ± 1.4 | |||
| HYP | 0.0 ± 0.0 (0.0–0.0) | −19.3 ± 1.4 | −17.5 ± 1.8 | −17.1 ± 2.1 | −8.0 ± 1.5 | −7.2 ± 2.2 | |||
| HOT | 0.0 ± 0.0 (0.0–0.0) | −21.7 ± 0.8 | −19.4 ± 1.4 | −16.9 ± 1.6 | −6.1 ± 2.1 | −1.8 ± 2.1 (−5.8 ~ 2.3) | |||
| HH | 0.0 ± 0.0 (0.0–0.0) | −20.8 ± 2.4 | −16.1 ± 1.7 | −15.1 ± 2.1 | −7.7 ± 2.2 | −2.8 ± 1.6 (−5.9 ~ 0.3) | |||
Values are means ± SE (95% CI).
p < .05 vs. Baseline.